Free Trial
LON:SN

Smith & Nephew (SN) Share Price, News & Analysis

GBX 1,198.50
+16.50 (+1.40%)
(As of 09/6/2024 ET)
Today's Range
1,183.50
1,203.50
50-Day Range
973
1,199
52-Week Range
N/A
Volume
1.51 million shs
Average Volume
343,671 shs
Market Capitalization
£10.45 billion
P/E Ratio
4,438.89
Dividend Yield
2.50%
Price Target
GBX 3,956.20

Smith & Nephew MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
230.1% Upside
GBX 3,956.20 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
0.53mentions of Smith & Nephew in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.10 out of 5 stars

SN stock logo

About Smith & Nephew Stock (LON:SN)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

SN Stock Price History

SN Stock News Headlines

China Stockpiling Gold “Like No Tomorrow”
For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… .
China Stockpiling Gold “Like No Tomorrow”
For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… .
Smith & Nephew Share News (SN.)
See More Headlines
Receive SN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
Consumer Goods
CIK
N/A
Fax
N/A
Employees
18,452
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 3,956.20
High Stock Price Target
£145
Low Stock Price Target
GBX 1,150
Potential Upside/Downside
+230.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
£305 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£5.64 billion
Cash Flow
GBX 64.15 per share
Book Value
GBX 596 per share

Miscellaneous

Free Float
N/A
Market Cap
£10.45 billion
Optionable
Not Optionable
Beta
0.62
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Deepak S. Nath Ph.D. (Age 52)
    CEO & Director
    Comp: $3.73M
  • Mr. John Terence Rogers (Age 55)
    CFO & Executive Director
  • Mr. Paul Connolly (Age 56)
    President of Global Operations
  • Mr. Andrew Swift
    Vice President of Investor Relations
  • Ms. Helen Barraclough (Age 45)
    Group General Counsel & Company Secretary
  • Ms. Alison Parkes (Age 52)
    Chief Compliance Officer & Compliance APAC
  • Mr. Joe Metzger
    Senior Vice President of Marketing Services & Communications
  • Mr. Philip G. Cowdy (Age 57)
    Chief Corporate Development & Corporate Affairs Officer
  • Ms. Elga Lohler (Age 56)
    Chief Human Resources Officer
  • Dr. Vasant Padmanabhan Ph.D. (Age 57)
    President of Research & Development and Ear, Nose & Throat

SN Stock Analysis - Frequently Asked Questions

How have SN shares performed this year?

Smith & Nephew's stock was trading at GBX 1,078.50 at the start of the year. Since then, SN stock has increased by 11.1% and is now trading at GBX 1,198.50.
View the best growth stocks for 2024 here
.

How do I buy shares of Smith & Nephew?

Shares of SN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Smith & Nephew own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Smith & Nephew investors own include Imperial Brands (IMB), Smith & Nephew (SNN), Alexion Pharmaceuticals (ALXN), Barclays (BARC), GSK (GSK), Diageo (DGE) and Standard Chartered (STAN).

This page (LON:SN) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners